FDA 483 - Paul W. Wallace, MD - March 17, 2026

An FDA inspection of Paul W. Wallace, MD in Los Angeles, CA, revealed significant deviations from investigational plans. The firm failed to complete numerous required procedures and assessments for multiple subjects across two protocols. Additionally, a large number of enrolled subjects missed all study visits due to personnel changes, indicating a severe lack of adherence to clinical trial protocols.